StreetInsider.com News Articles

Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)

Mon, 20 Jul 2026 08:40:00 -0400

Piper Sandler analyst David Amsellem reiterated an Overweight rating and $42.00 price target on Teva Pharma (NYSE: TEVA).

The analyst commented: "We co-hosted a webinar featuring a leading dermatologist who manages a sizable number of patients with vitiligo (and leads a large academic-based practice). The commentary on Teva's IL-15-directed antibody TEV-'408 was favorable (refer to our note on 7/7/26 for more details on the recently announced Phase Ib results for TEV-'408 in non-segmental vitiligo (NSV)). Put differently, the mechanistic rationale here is sound. Our featured key opinion leader (KOL) was even more enthusiastic about the underlying mechanism of Forte's (FBRX; not

Piper Sandler Reiterates Overweight Rating on Teva Pharma (TEVA)

Mon, 20 Jul 2026 08:38:57 -0400

Piper Sandler analyst David Amsellem reiterated an Overweight rating and $42.00 price target on Teva Pharma (NYSE: TEVA).

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Form 4 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Fri, 17 Jul 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260717/26784698.html

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Form 3 Immuneering Corp For: Jul 16 Filed by: Gengos Andrew

Thu, 16 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260716/26779778.html

Teva lawsuit against Eli Lilly over Forteo revived by appeals court

Mon, 13 Jul 2026 15:27:34 -0400

Investing.com -- A federal appeals court on Monday allowed Teva Pharmaceuticals to continue its lawsuit against Eli Lilly over allegations that Lilly violated a settlement agreement related to a generic version of the osteoporosis drug Forteo.

The 7th U.S. Circuit Court of Appeals in Chicago reversed a lower court decision that had dismissed the case. The appeals court found that questions about when the settlement agreement expired cannot be resolved in Lilly's favor based solely on the agreement's text and the complaint.

Lilly initially sued Teva in 2016, claiming that Teva's proposed generic version of Forteo would infringe on Lilly's patents. The

Teva lawsuit against Eli Lilly over Forteo revived by appeals court

Mon, 13 Jul 2026 15:27:34 -0400

Lilly initially sued Teva in 2016, claiming that Teva's proposed generic version of Forteo would infringe on Lilly's patents. The

UBS Reiterates Buy Rating on Teva Pharma (TEVA) as Pipeline Opportunities Broaden

Fri, 26 Jun 2026 09:35:05 -0400

UBS analyst Ashwani Verma reiterated a Buy rating and $42.00 price target on Teva Pharma (NYSE: TEVA).

The analyst commented, "We believe TEVA stock can continue to outperform in 2H26 and 2027 on broadening of pipeline opportunities, that can drive further multiple rerating. We highlight several key dynamics to watch: Potential good news on TL1a: Given the fact pattern, we believe MRK's TL1a full Ph3 Ulcerative Colitis data could serve as a potential positive catalyst for TEVA. MRK announced its positive topline but full data could come at a 2H26 Conference such as ACG (Oct, Nashville) or UEG (Oct, Barcelona). Further,

Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.

Wed, 24 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260624/26685623.html

Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.

Wed, 24 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260624/26685623.html

Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.

Wed, 24 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260624/26685623.html

Form 4 Immuneering Corp For: Jun 23 Filed by: Zeskind Benjamin J.

Wed, 24 Jun 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260624/26685623.html

Form 4 TEVA PHARMACEUTICAL INDU For: Jun 18 Filed by: Shields Matthew

Mon, 22 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260622/26672869.html

Form 4 TEVA PHARMACEUTICAL INDU For: Jun 18 Filed by: Shields Matthew

Mon, 22 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260622/26672869.html

Form 4 TEVA PHARMACEUTICAL INDU For: Jun 18 Filed by: Shields Matthew

Mon, 22 Jun 2026 16:01:00 -0400

si-local-file:///var/storage/secattach/20260622/26672869.html

Teva submits NDA for ecopipam to treat pediatric Tourette syndrome

Thu, 18 Jun 2026 16:58:01 -0400

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, an investigational treatment for pediatric Tourette syndrome, the company announced June 18, 2026.

Ecopipam is a selective dopamine D1 receptor antagonist and has received FDA Orphan Drug and Fast Track designations for the treatment of pediatric patients with Tourette syndrome. Orphan Drug designation applies to conditions affecting populations of 200,000 or fewer.

The NDA is supported by Phase 3 data published in JAMA Neurology, which showed ecopipam significantly delayed time to relapse compared with placebo in pediatric patients

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Thu, 18 Jun 2026 16:56:00 -0400

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations
Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.

TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam, a

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Thu, 18 Jun 2026 16:56:00 -0400

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations
Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Thu, 18 Jun 2026 16:56:00 -0400

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations
Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.

Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome

Thu, 18 Jun 2026 16:56:00 -0400

NDA submission supported by positive Phase 3 data recently published in JAMA Neurology.
Ecopipam is a first-in-class selective dopamine D1 receptor antagonist with a novel mechanism of action and has received FDA Orphan Drug and Fast Track designations
Ecopipam could be the first FDA-approved treatment option for pediatric Tourette syndrome in more than a decade, if approved.